Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 83 Debt-to-Equity is 0.01 as of Dec. 2025, which is at its 10-year median of 0.01. GuruFocus rates HAWPF with a GF Score™ of 83/100 and a GF Value™ of $9.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 814 Drug Manufacturers companies, Haw Par ranks better than 99.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Haw Par's Debt-to-Equity or its related term are showing as below:
HAWPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Haw Par was 0.02. The lowest was 0.00. And the median was 0.01.
HAWPF's Debt-to-Equity is ranked better than 99.88% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs HAWPF: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Haw Par Debt-to-Equity Related Terms
Haw Par Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Haw Par's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Haw Par's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a Debt-to-Equity of 0.01 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Haw Par and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, Haw Par ranks #1 out of 814 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Haw Par's Debt-to-Equity too high?
Haw Par's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Haw Par's value of 0.01 is 96.4% below this industry median. Based on the distribution chart, Haw Par ranks #1 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #1 out of 814 companies for Debt-to-Equity. This places Haw Par in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Haw Par's value of 0.01 is 96.4% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.28, Haw Par has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Debt-to-Equity of 0.01 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (HAWPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.29, compared to a current price of $12.58 — trading 35.4% above its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 96.4% below the Drug Manufacturers industry median of 0.28. Haw Par's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Haw Par (HAWPF), the current Debt-to-Equity is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.58 is trading 35.4% above its estimated GF Value™ of $9.29.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for HAWPF:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: $9.29 vs. price of $12.58 (35.4% above fair value)
Industry Position: 96.4% below the Drug Manufacturers median (#1 of 814)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
83GF Score
Get the complete analysis for HAWPF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
